AbCellera boosts IPO target second time in a week, seeking to raise US$483 - Technology | Business in Vancouver
IPO Launch: AbCellera Biologics Readies $357 Million IPO - IPOs On TheStreet - U.S. IPO Research & Opinion
IPO Stock AbCellera Eyes Profitability As Covid-19 Antibody Sales Soar | Investor's Business Daily
AbCellera Biologics to raise up to US $391M from NASDAQ IPO at up to US $4.52B valuation - Private Capital Journal
Vancouver-based AbCellera Goes Public on Nasdaq with Massive US $555.5M IPO, Company's Market Value Triples to $15.7 Billion on 1st Day | T-Net News
BioCentury - AbCellera valuation tops $15B as 2020's IPO class nears completion
COVID-19 Antibody Discovery Company Preps for Massive $391 Million IPO | BioSpace
AbCellera, tapped by Lilly for its COVID-19 antibody therapy, sets IPO terms with $5B valuation | Fierce Biotech
Pre-IPO: Everything You Need To Know About AbCellera (Part I) (NASDAQ:ABCL) | Seeking Alpha
Vancouver biotech company AbCellera's IPO nets $556M | Venture
COVID-19 roundup: AbCellera considering IPO as early as fall - The Logic
Thiel-backed therapy developer AbCellera looks to raise up to $391 million in IPO | Reuters
AbCellera: Why I Don't Love This Drug Discoverer's Business Model (NASDAQ:ABCL) | Seeking Alpha
/cloudfront-us-east-1.images.arcpublishing.com/tgam/SXPTX25NH5BV5HCRRZ2OZZOU3Y.jpg "With historic financing, AbCellera becomes champion of Canada's surging biotechnology sector - The Globe and Mail")
With historic financing, AbCellera becomes champion of Canada's surging biotechnology sector - The Globe and Mail
Peter Thiel Is Said to Get Board Seat at AbCellera as IPO Nears - BNN Bloomberg
AbCellera - Products, Competitors, Financials, Employees, Headquarters Locations
IPO Launch: AbCellera Biologics Readies $357 Million IPO - IPOs On TheStreet - U.S. IPO Research & Opinion
DoorDash, Airbnb Lead Big IPO Week—but Peter Thiel's AbCellera Could Be the Winner | Barron's
Wish & AbCellera Biologics Inc: Investors' Hawk-eyed On These 2 IPOs | Kalkine Media
AbCellera IPO: Stock to Fund COVID Antibody Therapy
